Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The cancer genetic testing services provider, NeoGenomics has launched the first molecular assay, NeoType CLL for clinical use in the US, which detects mutations in the SF3B1 gene (splicing factor 3b, subunit 1).
Subscribe to our email newsletter
The assay will offer stand-alone test in conjunction with a new comprehensive prognostic profiling panel for patients with chronic lymphocytic leukemia (CLL).
The CLL Profile panel also includes assays for IgVH mutation analysis, ZAP-70 expression and FISH tests that target abnormalities of certain genes associated with CLL.
The NeoType CLL profile is the company’s first hematology profiling test panel.
SF3B1 mutation analysis is also important to diagnose and determine prognosis in patients with myelodysplastic syndrome (MDS).
NeoGenomics chairman and CEO Douglas VanOort said the offering is part of NeoGenomics commitment to be on the leading edge of cancer genetics testing with menu of services.
”Our new NeoTYPE Cancer Profile tests are designed to provide physicians with comprehensive information about the biology and potential clinical behavior of specific cancers so patients can be offered the best quality personalized management and therapies that are targeted to their specific cancers." VanOort added.
NeoGenomics chief medical officer and director of research and development Maher Albitar said chronic lymphocytic leukemia can have different severity depending on the genomic makeup of the leukemic cells.
”Our goal is to provide patients and their treating physicians with the most comprehensive prognostic indicators available so that treatment options and management can be well planned and precisely tailored for each individual patient, " Albitar added.